Screening key microRNAs for castration-resistant prostate cancer based on miRNA/mRNA functional synergistic network

High-throughput methods have been used to explore the mechanisms by which androgen-sensitive prostate cancer (ASPC) develops into castration-resistant prostate cancer (CRPC). However, it is difficult to interpret cryptic results by routine experimental methods. In this study, we performed systematic and integrative analysis to detect key miRNAs that contribute to CRPC development. From three DNA microarray datasets, we retrieved 11 outlier microRNAs (miRNAs) that had expression discrepancies between ASPC and CRPC using a specific algorithm. Two of the miRNAs (miR-125b and miR-124) have previously been shown to be related to CRPC. Seven out of the other nine miRNAs were confirmed by quantitative PCR (Q-PCR) analysis. MiR-210, miR-218, miR-346, miR-197, and miR-149 were found to be over-expressed, while miR-122, miR-145, and let-7b were under-expressed in CRPC cell lines. GO and KEGG pathway analyses revealed that miR-218, miR-197, miR-145, miR-122, and let-7b, along with their target genes, were found to be involved in the PI3K and AKT3 signaling network, which is known to contribute to CRPC development. We then chose five miRNAs to verify the accuracy of the analysis. The target genes of each miRNA were altered significantly upon transfection of specific miRNA mimics in the C4–2 CRPC cell line, which was consistent with our pathway analysis results. Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins, and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development.

[1]  C. Tepper,et al.  microRNAs and prostate cancer , 2008, Journal of cellular and molecular medicine.

[2]  Jiajia Chen,et al.  Identification of novel microRNA regulatory pathways associated with heterogeneous prostate cancer , 2013, BMC Systems Biology.

[3]  Yuhchyau Chen,et al.  Increased Chemosensitivity via Targeting Testicular Nuclear Receptor 4 (TR4)-Oct4-Interleukin 1 Receptor Antagonist (IL1Ra) Axis in Prostate Cancer CD133+ Stem/Progenitor Cells to Battle Prostate Cancer* , 2013, The Journal of Biological Chemistry.

[4]  Bairong Shen,et al.  Translational Bioinformatics for Diagnostic and Prognostic Prediction of Prostate Cancer in the Next-Generation Sequencing Era , 2013, BioMed research international.

[5]  X. Yao,et al.  Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. , 2013, Asian journal of andrology.

[6]  Clifford A. Meyer,et al.  Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer , 2009, Cell.

[7]  W. Gerald,et al.  Microarray analysis of prostate cancer progression to reduced androgen dependence: Studies in unique models contrasts early and late molecular events , 2004, Molecular carcinogenesis.

[8]  Shafiq A. Khan,et al.  Vascular endothelial growth factor A, secreted in response to transforming growth factor-β1 under hypoxic conditions, induces autocrine effects on migration of prostate cancer cells. , 2012, Asian journal of andrology.

[9]  R. Dahiya,et al.  The functional significance of microRNA-145 in prostate cancer , 2010, British Journal of Cancer.

[10]  Daniel Bottomly,et al.  Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation , 2013, PloS one.

[11]  E. Bruckheimer,et al.  TGF‐β signaling and androgen receptor status determine apoptotic cross‐talk in human prostate cancer cells , 2008, The Prostate.

[12]  Heidi Ledford.  Cancer: The Ras renaissance , 2015, Nature.

[13]  Ying Wang,et al.  Molecular Signature of Cancer at Gene Level or Pathway Level? Case Studies of Colorectal Cancer and Prostate Cancer Microarray Data , 2013, Comput. Math. Methods Medicine.

[14]  Bairong Shen,et al.  Identification of MicroRNA as Sepsis Biomarker Based on miRNAs Regulatory Network Analysis , 2014, BioMed research international.

[15]  Yajun Yi,et al.  Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy , 2005, Clinical Cancer Research.

[16]  G. Mills,et al.  miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-α in human breast cancer cells , 2010, Cell Death and Differentiation.

[17]  N. Kyprianou,et al.  Detection of microRNAs in prostate cancer cells by microRNA array. , 2011, Methods in molecular biology.

[18]  C. Tepper,et al.  miR‐125b promotes growth of prostate cancer xenograft tumor through targeting pro‐apoptotic genes , 2011, The Prostate.

[19]  W. Heo,et al.  p21-Activated kinase 4 promotes prostate cancer progression through CREB , 2013, Oncogene.

[20]  S. Elledge,et al.  Identification of SCF Ubiquitin Ligase Substrates by Global Protein Stability Profiling , 2008, Science.

[21]  W. Oh,et al.  Targeting the androgen receptor signalling axis in castration‐resistant prostate cancer (CRPC) , 2012, BJU international.

[22]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.

[23]  C. Croce,et al.  MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. , 2009, Cancer research.

[24]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[25]  Ying Wang,et al.  Identifying novel prostate cancer associated pathways based on integrative microarray data analysis , 2011, Comput. Biol. Chem..

[26]  R. Cardiff,et al.  Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. , 2012, Cancer research.

[27]  W. Gerald,et al.  Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. , 2008, The Journal of clinical investigation.

[28]  Bairong Shen,et al.  Identification of candidate miRNA biomarkers from miRNA regulatory network with application to prostate cancer , 2014, Journal of Translational Medicine.

[29]  F. Schröder,et al.  Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. , 2008, European urology.

[30]  Bairong Shen,et al.  Integrative analysis reveals disease-associated genes and biomarkers for prostate cancer progression , 2014, BMC Medical Genomics.

[31]  K. Griffiths,et al.  Endocrine treatment of prostate cancer. , 1989, Progress in medicinal chemistry.

[32]  S. Alahari,et al.  miRNA control of tumor cell invasion and metastasis , 2010, International journal of cancer.

[33]  C. Lee,et al.  Transforming growth factor-beta1 inhibits membrane association of protein kinase C alpha in a human prostate cancer cell line, PC3. , 1997, Endocrinology.

[34]  H. Scher,et al.  Targeting the androgen receptor pathway in prostate cancer. , 2008, Current opinion in pharmacology.

[35]  Chawnshang Chang,et al.  Androgen receptor enhances entosis, a non‐apoptotic cell death, through modulation of Rho/ROCK pathway in prostate cancer cells , 2013, The Prostate.

[36]  Andrew J Armstrong,et al.  Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. , 2013, Endocrine-related cancer.

[37]  C. Cooper,et al.  Rho GTPases in PC-3 prostate cancer cell morphology, invasion and tumor cell diapedesis , 2008, Clinical & Experimental Metastasis.

[38]  Y. Li,et al.  Global analysis of differentially expressed genes in androgen-independent prostate cancer , 2007, Prostate Cancer and Prostatic Diseases.

[39]  H. Lilja,et al.  miR‐34c is downregulated in prostate cancer and exerts tumor suppressive functions , 2010, International journal of cancer.

[40]  F. Zhao,et al.  Characterization of the Small RNA Transcriptomes of Androgen Dependent and Independent Prostate Cancer Cell Line by Deep Sequencing , 2010, PloS one.

[41]  G. Kristiansen,et al.  Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma , 2009, International journal of cancer.

[42]  Bairong Shen,et al.  Post genome-wide association studies functional characterization of prostate cancer risk loci , 2013, BMC Genomics.

[43]  F. Gao,et al.  TGFβ1 induces apoptosis in invasive prostate cancer and bladder cancer cells via Akt-independent, p38 MAPK and JNK/SAPK-mediated activation of caspases. , 2012, Biochemical and biophysical research communications.

[44]  Christopher P Evans,et al.  An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells , 2007, Proceedings of the National Academy of Sciences.

[45]  Peilin Jia,et al.  Key regulators in prostate cancer identified by co-expression module analysis , 2014, BMC Genomics.

[46]  J. Xia,et al.  Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre. , 2010, Asian journal of andrology.

[47]  G. Sauter,et al.  Prognostic relevance of Bcl‐2 overexpression in surgically treated prostate cancer is not caused by increased copy number or translocation of the gene , 2012, The Prostate.

[48]  Concetto Spampinato,et al.  Combining literature text mining with microarray data: advances for system biology modeling , 2012, Briefings Bioinform..

[49]  C. Myers,et al.  Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. , 2000, Biochemical and biophysical research communications.

[50]  J. Li,et al.  RalA regulates vascular endothelial growth factor-C (VEGF-C) synthesis in prostate cancer cells during androgen ablation , 2007, Oncogene.

[51]  M. Ittmann,et al.  Targeting Fibroblast Growth Factor Receptor Signaling Inhibits Prostate Cancer Progression , 2012, Clinical Cancer Research.

[52]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[53]  Xin-yang Wang,et al.  Prostate-targeted mTOR-shRNA inhibit prostate cancer cell growth in human tumor xenografts. , 2013, International journal of clinical and experimental medicine.

[54]  C. Creighton,et al.  Widespread deregulation of microRNA expression in human prostate cancer , 2008, Oncogene.

[55]  P. Nelson,et al.  The androgen/androgen receptor axis in prostate cancer , 2012, Current opinion in oncology.

[56]  J. Kreisberg,et al.  Akt in prostate cancer: possible role in androgen-independence. , 2003, Current drug metabolism.

[57]  T. Tammela,et al.  MicroRNA expression profiling in prostate cancer. , 2007, Cancer research.

[58]  C. Stournaras,et al.  Rho/ROCK/actin signaling regulates membrane androgen receptor induced apoptosis in prostate cancer cells. , 2008, Experimental cell research.

[59]  Jiajia Chen,et al.  Clear cell renal cell carcinoma associated microRNA expression signatures identified by an integrated bioinformatics analysis , 2013, Journal of Translational Medicine.

[60]  R. Plasterk,et al.  The diverse functions of microRNAs in animal development and disease. , 2006, Developmental cell.

[61]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[62]  Guo-Jun Zhang,et al.  Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex , 2004, Nature.

[63]  K. Burnstein,et al.  Novel Interaction between the Co-chaperone Cdc37 and Rho GTPase Exchange Factor Vav3 Promotes Androgen Receptor Activity and Prostate Cancer Growth* , 2012, The Journal of Biological Chemistry.

[64]  Peilin Jia,et al.  Top associated SNPs in prostate cancer are significantly enriched in cis-expression quantitative trait loci and at transcription factor binding sites , 2014, Oncotarget.

[65]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Manfred Kunz,et al.  MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth , 2008, Cell Research.

[67]  Yusuke Nakamura,et al.  Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. , 2007, Cancer research.

[68]  T. Hibi,et al.  MicroRNAs in Hepatobiliary and Pancreatic Cancers , 2011, Front. Gene..

[69]  Miguel Srougi,et al.  Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. , 2011, Urologic oncology.

[70]  J D Siegal,et al.  Enhanced expression of the c‐myc protooncogene in high‐grade human prostate cancers , 1988, The Prostate.

[71]  K. Waltering,et al.  Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. , 2009, Cancer research.

[72]  P. Shao,et al.  Genetic Variations in a PTEN/AKT/mTOR Axis and Prostate Cancer Risk in a Chinese Population , 2012, PloS one.

[73]  E. Bissonette,et al.  Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. , 2003, Cancer research.

[74]  Derrick J. Morton,et al.  TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. , 2013, Endocrinology.